SOPHiA GENETICS Past Earnings Performance
Past criteria checks 0/6
SOPHiA GENETICS's earnings have been declining at an average annual rate of -13.6%, while the Healthcare Services industry saw earnings growing at 14.8% annually. Revenues have been growing at an average rate of 21.3% per year.
Key information
-13.6%
Earnings growth rate
-3.6%
EPS growth rate
| Healthcare Services Industry Growth | 1.7% |
| Revenue growth rate | 21.3% |
| Return on equity | -55.0% |
| Net Margin | -102.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported, And Analysts Assigned A US$6.00 Price Target
Aug 09
Investors Still Waiting For A Pull Back In SOPHiA GENETICS SA (NASDAQ:SOPH)
Aug 08SOPHiA GENETICS SA (NASDAQ:SOPH) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mar 09Sophia Genetics: Breakthrough Potential In A Cautious Healthcare Sector
Feb 12Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Dec 27Why Investors Shouldn't Be Surprised By SOPHiA GENETICS SA's (NASDAQ:SOPH) 35% Share Price Surge
Nov 09Is SOPHiA GENETICS (NASDAQ:SOPH) In A Good Position To Invest In Growth?
Aug 08Here's Why We're Watching SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Dec 15SOPHiA GENETICS partnering with Boundless Bio on oncogene cancer therapies
Sep 21SOPHiA Genetics GAAP EPS of -$0.39 in-line, revenue of $11.7M misses by $0.25M
Aug 09We're Hopeful That SOPHiA GENETICS (NASDAQ:SOPH) Will Use Its Cash Wisely
Jul 01SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 18We Think SOPHiA GENETICS (NASDAQ:SOPH) Can Afford To Drive Business Growth
Mar 10Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Nov 24Revenue & Expenses Breakdown
How SOPHiA GENETICS makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 65 | -67 | 78 | 36 |
| 31 Mar 24 | 64 | -73 | 82 | 37 |
| 31 Dec 23 | 62 | -79 | 82 | 37 |
| 30 Sep 23 | 59 | -69 | 79 | 34 |
| 30 Jun 23 | 54 | -78 | 80 | 35 |
| 31 Mar 23 | 51 | -82 | 82 | 35 |
| 31 Dec 22 | 48 | -87 | 84 | 35 |
| 30 Sep 22 | 45 | -95 | 87 | 35 |
| 30 Jun 22 | 44 | -93 | 86 | 32 |
| 31 Mar 22 | 42 | -86 | 79 | 30 |
| 31 Dec 21 | 40 | -74 | 70 | 27 |
| 30 Sep 21 | 37 | -63 | 60 | 25 |
| 30 Jun 21 | 34 | -52 | 49 | 23 |
| 31 Mar 21 | 30 | -41 | 41 | 20 |
| 31 Dec 20 | 28 | -39 | 36 | 19 |
| 31 Dec 19 | 25 | -34 | 35 | 15 |
Quality Earnings: SOPH is currently unprofitable.
Growing Profit Margin: SOPH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SOPH is unprofitable, and losses have increased over the past 5 years at a rate of 13.6% per year.
Accelerating Growth: Unable to compare SOPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SOPH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (7.1%).
Return on Equity
High ROE: SOPH has a negative Return on Equity (-54.99%), as it is currently unprofitable.